All articles by Alex Watt
Alex Watt
Insights from ISPOR Europe 2023: Copenhagen
What became evident during the conference was the clear theme presented to attendees and described as “the nexus of policy and science.”
HTA outcomes in top European markets grow at a rate of 27% while focusing on oncology
During 2018–2022, more than 3,000 HTA decisions were made in the Europe top-5, and they steadily increased at an average annual growth rate (AAGR) of 27%.
Economic unrest results in an average pharmaceutical price trend of 1,123% in Lebanon
In Lebanon, drug prices are reviewed and determined by the Ministry of Public Health (MoPH) during the registration process.
Over 2,000 drugs in Japan undergo an average price reduction of 9.4% in April
Historically, Japan performs scheduled biannual price adjustments as a cost-reduction method.
Economic unrest results in an average pharmaceutical price trend of 1,123% in Lebanon
Branded medicines accounted for roughly 76% of Lebanon’s pharmaceutical market in 2022, according to GlobalData’s POLI database.
Risk-sharing agreements are growing at a rate of 24%
Risk-sharing agreements (RSAs) aim to mitigate the risks of including high-cost drugs on reimbursement lists and healthcare plans.
Medicines priced under the early access programme in France see prices drop by 16%
A review of 17 medicines first available via the early access scheme found their price negotiation caused an average cut of 15.9%.